Abstract
C-reactive protein (CRP), interleukin-6 (IL-6), and the -174 GC IL-6 gene polymorphism were analyzed after coronary angioplasty in 50 patients, 25 of whom were treated with the glycoprotein IIb/IIIa platelet receptor inhibitor eptifibatide for 24 hours. It was found that glycoprotein IIb/IIIa inhibition significantly blocked postangioplasty CRP increases in all patients but blocked IL-6 increases only in patients carrying the -174 GG genotype.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angioplasty, Balloon, Coronary*
-
C-Reactive Protein / analysis*
-
Coronary Disease / blood*
-
Coronary Disease / genetics
-
Coronary Disease / therapy
-
Eptifibatide
-
Female
-
Fibrinolytic Agents / pharmacology
-
Genotype
-
Humans
-
Inflammation Mediators / blood
-
Infusions, Intravenous
-
Interleukin-6 / blood*
-
Interleukin-6 / genetics*
-
Male
-
Middle Aged
-
Peptides / administration & dosage
-
Peptides / pharmacology*
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / pharmacology*
-
Platelet Glycoprotein GPIIb-IIIa Complex / administration & dosage
-
Platelet Glycoprotein GPIIb-IIIa Complex / pharmacology*
-
Polymorphism, Genetic*
-
Stents
Substances
-
Fibrinolytic Agents
-
Inflammation Mediators
-
Interleukin-6
-
Peptides
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
C-Reactive Protein
-
Eptifibatide